Description
Orladeyo (berotralstat) is a prescription medication used to prevent hereditary angioedema (HAE) attacks. It is a selective and reversible inhibitor of plasma kallikrein, which is responsible for generating the peptide bradykinin, a mediator of edema formation.
Uses:
Orladeyo is used to decrease the frequency of HAE attacks in adults and pediatric patients aged 12 years and older. It is not a treatment for an acute HAE attack.
Storage Conditions:
Orladeyo should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) in its original packaging. It should be protected from light and moisture. The medication should not be frozen. Once the medication is prepared, it can be stored at room temperature for up to 24 hours.
Mechanism of Action:
Orladeyo works by inhibiting plasma kallikrein, an enzyme that is part of the kallikrein-kinin system, which is involved in the regulation of blood pressure, inflammation, and pain. By blocking this enzyme, Orladeyo decreases the production of bradykinin, which prevents the formation of edema.
HOW TO USE:
Orladeyo is taken orally once daily with or without food. The medication should be taken at the same time every day. The dosage is based on the patient’s weight and is adjusted based on their response to treatment. Patients should follow their healthcare provider’s instructions carefully when taking Orladeyo.
Precautions:
• Patients should inform their healthcare provider if they are pregnant, planning to become pregnant, or breastfeeding.
• Patients with liver or kidney disease should use Orladeyo with caution and may need a reduced dosage.
• Orladeyo may increase the risk of bleeding, and patients with a bleeding disorder should use the medication with caution.
• Patients with a history of hypersensitivity to the medication or its ingredients should avoid taking Orladeyo.
Drug Interactions:
• Orladeyo may interact with other medications, such as blood thinners, which can increase the risk of bleeding.
• Patients should inform their healthcare provider of all the medications they are taking before starting Orladeyo.
Contraindications:
• Orladeyo should not be used in patients with active liver disease, including hepatitis B and C.
• It is not recommended for patients with severe kidney disease.
• Patients with a history of hypersensitivity to the medication or its components should not take Orladeyo.
Overdose:
There is limited information on the overdose of Orladeyo. However, patients who take a higher-than-prescribed dosage of Orladeyo should seek medical attention.
Adverse Reactions:
The most common adverse reactions experienced by patients taking Orladeyo include abdominal pain, vomiting, diarrhea, nausea, fatigue, and headache. Other potential side effects include upper respiratory tract infection, injection site reaction, and back pain. Patients should contact their healthcare provider if they experience any unusual symptoms while taking Orladeyo.
In conclusion, Orladeyo is a prescription medication used to prevent HAE attacks by blocking plasma kallikrein and reducing the production of bradykinin. It is taken orally once a day with or without food, and patients should follow their healthcare provider’s instructions carefully when taking Orladeyo. Before taking Orladeyo, patients should inform their provider of all medications they are taking and any medical conditions they have, including pregnancy or liver or kidney disease. Orladeyo should not be taken by patients with active liver disease or a history of hypersensitivity to the medication. Side effects of Orladeyo may include abdominal pain, vomiting, and headache, among others. As with any medication, patients should contact their healthcare provider if they experience any unusual symptoms while taking Orladeyo.
Reviews
There are no reviews yet.